STOCK TITAN
  1. Home
  2. Sec-filings
  3. IRON
  4. [Form 4] Disc Medicine, Inc. Insider Trading Activity

Disc Medicine (IRON) COO sells 9,096 shares at ~$83

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Disc Medicine, Inc. (IRON) reported that Chief Operating Officer Jonathan Yen-Wen Yu exercised stock options and sold the resulting common shares under a pre-arranged Rule 10b5-1 trading plan. On August 24, 2026, he exercised options for 300 shares of common stock at an exercise price of $13.50 per share and sold 300 shares at a weighted average price of $82.5333 per share, with sale prices ranging from $82.50 to $82.60. On August 25, 2026, he exercised options for an additional 8,796 shares at $13.50 per share and sold 8,796 shares at a weighted average price of $83.1164 per share, with sale prices ranging from $82.57 to $83.47. The options exercised were from a grant vesting in 48 equal monthly installments after December 29, 2022, and all reported trades were effected pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026.

Positive

  • None.

Negative

  • None.
Insider Yu Jonathan Yen-Wen
Role Chief Operating Officer
Sold 9,096 shs ($756K)
Approx. gross sale proceeds $756K
Approx. exercise cost $123K
Approx. pre-tax spread $633K
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F1, F4 8,796 $0.00 $0.00
Exercise Common Stock F1 8,796 $13.50 $119K
Sale Common Stock F1, F3 8,796 $83.1164 $731K
Exercise Stock Option (Right to Buy) F1, F4 300 $0.00 $0.00
Exercise Common Stock F1 300 $13.50 $4K
Sale Common Stock F1, F2 300 $82.5333 $25K
Holdings After Transaction: Stock Option (Right to Buy) — 13,847 shares (Direct); Common Stock — 54,324 shares (Direct)
Footnotes (4)
  1. F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026.
  2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.50 to $82.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) and (3) to this Form 4.
  3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.57 to $83.47, inclusive.
  4. F4. The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date.
Shares sold August 24, 2026 300 shares Common stock sold in open-market transactions on August 24, 2026
Weighted average sale price August 24, 2026 $82.5333 per share Common stock sales ranged from $82.50 to $82.60 per share
Shares sold August 25, 2026 8,796 shares Common stock sold in open-market transactions on August 25, 2026
Weighted average sale price August 25, 2026 $83.1164 per share Common stock sales ranged from $82.57 to $83.47 per share
Option exercise price $13.50 per share Exercise price for stock options converted into common stock
Total shares sold 9,096 shares Net shares sold across all reported sale transactions
Option vesting schedule 48 equal monthly installments Vesting following December 29, 2022, subject to continued service
Rule 10b5-1 plan adoption date March 17, 2026 Date the trading plan governing these transactions was adopted
Rule 10b5-1 trading plan regulatory
"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
vesting financial
"shares underlying this option vest in 48 equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

What insider transactions did IRON’s COO Jonathan Yen-Wen Yu report on this Form 4?
He reported exercising stock options for 9,096 shares of Disc Medicine common stock at an exercise price of $13.50 per share and selling 9,096 shares in open-market transactions on August 24–25, 2026 at weighted average prices around $82–83 per share.

On what dates did the reported IRON stock transactions occur?
The transactions in Disc Medicine (IRON) stock occurred on August 24, 2026 and August 25, 2026. On each date, Jonathan Yen-Wen Yu exercised stock options and sold the resulting common shares in multiple open-market transactions.

What prices were received for the IRON shares sold in these transactions?
On August 24, 2026, 300 shares were sold at a weighted average price of $82.5333, within a range of $82.50–$82.60. On August 25, 2026, 8,796 shares were sold at a weighted average price of $83.1164, within a range of $82.57–$83.47.

What was the exercise price of the Disc Medicine (IRON) stock options used in these trades?
The stock options exercised by Jonathan Yen-Wen Yu to acquire Disc Medicine (IRON) common shares had an exercise price of $13.50 per share. They were exercised for 300 shares on August 24, 2026 and 8,796 shares on August 25, 2026.

Were the IRON insider transactions made under a Rule 10b5-1 trading plan?
Yes. The filing states that the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026, and the Rule 10b5-1 checkbox for the reporting person is affirmed.

How do the stock options in this IRON Form 4 vest?
The options underlying these transactions vest in 48 equal monthly installments following December 29, 2022, subject to Jonathan Yen-Wen Yu’s continued service on each vesting date, according to the filed footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Yu Jonathan Yen-Wen
(Last)(First)(Middle)
C/O DISC MEDICINE, INC.
321 ARSENAL STREET, SUITE 101
(Street)
WATERTOWN MASSACHUSETTS 02472
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Disc Medicine, Inc. [ IRON ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Operating Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/24/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/24/2026M(1)300A$13.554,624D
Common Stock08/24/2026S(1)300D$82.5333(2)54,324D
Common Stock08/25/2026M(1)8,796A$13.563,120D
Common Stock08/25/2026S(1)8,796D$83.1164(3)54,324D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$13.508/24/2026M(1)300 (4)12/28/2032Common Stock300$022,643D
Stock Option (Right to Buy)$13.508/25/2026M(1)8,796 (4)12/28/2032Common Stock8,796$013,847D
Explanation of Responses:
1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.50 to $82.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) and (3) to this Form 4.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.57 to $83.47, inclusive.
4. The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date.
By: /s/ Rahul Khara, as Attorney-in-Fact08/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR